Assessment of peripheral endothelial function predicts future risk of solid-tumor cancer

• Published in: European journal of preventive cardiology Vol. 27; no. 6; p. 608
• Main Authors: Toya, Takumi, Sara, Jaskanwal D, Corban, Michel T, Taher, Riad, Godo, Shigeo, Herrmann, Joerg, Lerman, Lilach O, Lerman, Amir
• Format: Journal Article
• Language: English
• Published: England 01.04.2020
• Subjects: Adult; Aged; Endothelium, Vascular - physiopathology; Female; Humans; Hyperemia - physiopathology; Incidence; Male; Manometry; Microvessels - physiopathology; Middle Aged; Neoplasms - diagnosis; Neoplasms - epidemiology; Peripheral Arterial Disease - diagnosis; Peripheral Arterial Disease - epidemiology; Peripheral Arterial Disease - physiopathology; Predictive Value of Tests; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; United States - epidemiology; Vasodilation; United States; vascular endothelium-dependent relaxation; cancer; microvessel abnormalities; Cardiovascular diseases
• DOI: 10.1177/2047487319884246

Cardiovascular health metrics predict the risk not only of cardiovascular diseases but also of several types of cancers. Microvascular endothelial dysfunction can predict future cardiovascular adverse events, but the predictive value of microvascular endothelial dysfunction for future risk of solid-tumor cancer has not been characterized. A total of 488 patients who underwent microvascular endothelial function assessment using reactive hyperemia peripheral arterial tonometry were included in this study. Microvascular endothelial dysfunction was defined as a reactive hyperemia peripheral arterial tonometry index ≤2.0. Of 221 patients with a baseline reactive hyperemia peripheral arterial tonometry index ≤2.0, 21 patients (9.5%) were diagnosed with incident solid-tumor cancer during follow-up, whereas of 267 patients with a baseline reactive hyperemia peripheral arterial tonometry index >2.0, 10 patients (3.7%) were diagnosed with incident solid-tumor cancer during follow-up (  = 0.009). Patients with a reactive hyperemia peripheral arterial tonometry index ≤2.0 had lower solid-tumor cancer-free survival compared to patients with a reactive hyperemia peripheral arterial tonometry index >2.0 (log-rank  = 0.017) (median follow-up 6.0 (3.0-9.1) years). Cox proportional hazard analyses showed that a reactive hyperemia peripheral arterial tonometry index ≤2.0 predicted the incidence of solid-tumor cancer, with a hazard ratio of 2.52 (95% confidence interval 1.17-5.45;  = 0.019) after adjusting for age, sex, and coronary artery disease, 2.83 (95% confidence interval 1.30-6.17;  = 0.009) after adjusting for diabetes mellitus, hypertension, smoking status, and body mass index >30 kg/m , 2.79 (95% confidence interval 1.21-6.41;  = 0.016) after adjusting for fasting plasma glucose, systolic blood pressure, smoking status (current or former), and body mass index, and 2.43 (95% confidence interval 1.10-5.34;  = 0.028) after adjusting for Framingham risk score. Microvascular endothelial dysfunction, as defined by a reactive hyperemia peripheral arterial tonometry index ≤2.0, was associated with a greater than two-fold increased risk of solid-tumor cancer. Microvascular endothelial dysfunction may be a useful marker to predict the future risk of solid-tumor cancer, in addition to its known ability to predict cardiovascular disease. Further research is necessary to develop adequate cancer screening strategies for patients with microvascular endothelial dysfunction.